Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yunzhong Pharmaceutical (Guangdong Yunzhong Pharmaceutical Co., Ltd.) is an innovative biopharmaceutical company established in 2017 and headquartered in Huizhou, Guangdong. It serves as a strategic R&D and industrialization hub for its parent company, HitGen Inc., focusing on the discovery and development of small molecule innovative drugs for oncology and inflammatory diseases. The company leverages advanced DNA-Encoded Library (DEL) technology and other high-throughput screening platforms to identify and optimize novel lead compounds. Its clinical-stage pipeline includes HG146, a selective HDAC inhibitor, and HG030, a second-generation NTRK/ROS1 inhibitor. Yunzhong Pharmaceutical operates research and pilot manufacturing facilities to advance candidates through clinical development toward commercialization.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yunzhong Pharmaceutical.